Moexa Pharmaceuticals Limited (Moexa) is a multi national drug research and development company engaging in proprietary TGF-β/Smad3 signaling technology. We have pioneered this innovative treatment to address unmet medical needs in cancer immunotherapy, and in fibrotic disease.
The TGF-β/Smad3 pathway, is associated with tumor progression and fibrotic disease including lung fibrosis and cystic fibrosis. We have developed and continue to create and refine novel therapeutics focusing on the TGF-β/Smad3 signaling pathway.
Our proprietary small molecule Smad3 inhibitors demonstrate strong efficacy in pre-clinical animal model for cancers, and in preliminary tests for lung fibrosis. We have solid patents in place protecting our IP as we continue to expand our pipeline as we advance towards clinical trials.